Loading
A phase 1/2 trial of SHR-A1921, SHR-A2009, Aumolertinib, Pemetrexed, Carboplatin and Adebrelimab in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06474455 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 156 participants planned, started 2024-07-02 and due to reach its primary completion in 2029-06. Interventions recorded: SHR-9839 for Injection, SHR-A1921 for Injection, SHR-A2009 for Injection, Almonertinib Mesilate Tablets, Pemetrexed Disodium for Injection and Carboplatin for injection.
Shares SHR-A1921, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2009, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Pemetrexed, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.